These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33099852)

  • 1. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
    Croce S; Chibon F
    Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
    Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
    Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
    Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
    Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
    Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
    J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas.
    Croce S; Lesluyes T; Valle C; M'Hamdi L; Thébault N; Pérot G; Stoeckle E; Noël JC; Fontanges Q; Devouassoux-Shisheboran M; Querleu D; Guyon F; Floquet A; Chakiba C; Mayeur L; Rebier F; MacGrogan GM; Soubeyran I; Le Guellec S; Chibon F
    Clin Cancer Res; 2020 Feb; 26(4):855-861. PubMed ID: 31796515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
    Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
    Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
    Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
    Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
    Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
    Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
    Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
    Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
    Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
    Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis.
    Cao HY; Yang S; Wang S; Deng LY; Lou JY
    Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28340268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential.
    Conconi D; Chiappa V; Perego P; Redaelli S; Bovo G; Lavitrano M; Milani R; Dalprà L; Lissoni AA
    Oncol Rep; 2017 Jan; 37(1):41-47. PubMed ID: 28004108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
    Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
    Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
    Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
    Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
    Ravegnini G; Mariño-Enriquez A; Slater J; Eilers G; Wang Y; Zhu M; Nucci MR; George S; Angelini S; Raut CP; Fletcher JA
    Mod Pathol; 2013 May; 26(5):743-9. PubMed ID: 23222489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
    Deng ZJ; Guo LN
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
    [No Abstract]   [Full Text] [Related]  

  • 20. POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY.
    Tanabe Y; Hayashi T; Okada M; Aburatani H; Tonegawa S; Abiko K; Konishi I
    Georgian Med News; 2024 May; (350):42-48. PubMed ID: 39089269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.